KR101622032B1 - Pharmaceutical composition comprising Cymbidium extract for preventing or treating muscle atrophy - Google Patents

Abstract

Cymbidium (Cymbidium) A pharmaceutical composition for amyotrophic prevention, treatment or improvement containing the extract as an active ingredient, food composition, and the dietary relates to a food composition, Cymbidium (Cymbidium) extract muscle damage, necrosis and apoptosis (apoptosis) And exhibits an anti-atrophic effect, thus being applicable not only to the development of cosmic foods but also as an effective ingredient for preventing, treating or ameliorating atrophy.

Description

[0001] The present invention relates to a pharmaceutical composition for preventing or treating muscle atrophy comprising cymbidium extract as an active ingredient,

The present invention relates to a pharmaceutical composition and a food composition for improving or treating atrophy comprising an extract of Cymbidium as an active ingredient. The extract of Cymbidium inhibits myocardial damage, necrosis and apoptosis, And can be used as an effective ingredient for preventing, treating or ameliorating atrophy.

Atrophy can be defined as loss of muscle tissue caused by not using muscles or damage to the nerves that dominate the muscles or muscles themselves. In general, the muscles are not used, resulting in severe muscle strength loss and gradually progressing to muscle atrophy. In addition, people living in places without gravity also suffer from muscle weakness May be seen in some cases. Myasthenia gravis, dystrophy: Progressive muscular dystrophy, myotonic dystrophy, Duchen type, Becker type, bony type, facial shoulder brachial type, and inflammation of the muscle itself. And muscular atrophy caused by damage to the nerves is caused by spinal muscular amyotrophy: Verdney-Hoffmann type, Kugelberg-Velenders disease, amyotrophic lateral sclerosis (ALS) Lou Gehrig's disease, spinobular muscular atrophy, and Kennedy's disease.

The causes of muscle atrophy have not yet been clarified. The causes of muscle atrophy are as follows: muscle cell damage due to oxidant increase, decrease of muscle protein production and regeneration due to decrease of stress protein expression, proteasome ubiquitin And promoting the degradation of the muscle protein upon activation of proteosomal ubiquitination.

Muscle dystrophy associated with degenerative muscular dystrophy is a rare disease in which there are about 30,000 patients in the US and Europe. There is no drug currently on the market as a fundamental treatment for this disease. Natural extracts are ideal as a drug for lifelong ingestion at the time when no clear treatment for these atrophy patients has been developed. In addition, as the aging and space age, which are based on state-of-the-art technologies, has come, the problem of gradual atrophy has gradually become a problem. Therefore, the pharmaceutical composition according to the present invention is expected to be usefully used for rehabilitation of patients having muscle atrophy and physical disability, and the identification of effective ingredient materials through natural products without side effects has not only high value in research, I think it will help.

Cymbidium originated in Southeast Asia, China, Japan, New Guinea, northern Australia, and consists of two petals, one petal, and three calyxes, flowers, knife-shaped leaves, And roots like thick rope. It has been reported that it has more negative ion generation and higher relative humidity than Siberiania, so it has excellent air purification and humidification ability. In addition, it has been developed and sold as a hair regeneration product, hair shampoo, etc. in Japan, and the results of these studies have been reported in Korea.

On the other hand, U.S. Patent No. 7,732,410 for atherosclerosis inhibiting composition and U.S. Patent No. 7,674,832 for a composition for promoting wound healing and treating psoriasis respectively show that the cymbidium extract may be included as an additional component And US Patent Publication No. 2013-0302450 discloses a cymbidium extract as an active ingredient of an agent having hair growth and growth effect and anti-whitening effect.

However, there have been no reported cases of Cymbidium extracts for use in the prevention, treatment, or rehabilitation of muscle atrophy.

Accordingly, the inventors of the present invention found through experiments that Cymbidium extract inhibits myocardial damage, necrosis and apoptosis during the course of the research, thereby providing cymbidium extract as a pharmaceutical composition for preventing or treating muscle atrophy , A food composition for improvement, and a health functional food composition. The present invention has been accomplished on the basis of this finding.

U.S. Patent No. 7,732,410 U.S. Patent No. 7,674,832 U.S. Published Patent Application No. 2013-0302450

It is an object of the present invention to provide novel uses of Cymbidium extract as a new material for preventing, treating or ameliorating muscle atrophy by demonstrating the activity of inhibiting myocardial damage, necrosis and apoptosis.

In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing or treating muscle atrophy comprising cymbidium extract as an active ingredient.

Further, the present invention provides a food composition for preventing or improving muscle atrophy comprising cymbidium extract as an active ingredient.

The present invention also provides a health functional food composition for preventing or ameliorating atrophy comprising cymbidium extract as an active ingredient.

Cymbidium extract inhibits myocardial damage, necrosis and apoptosis and exhibits an anti-atrophic effect, so that it can be applied not only to the development of cosmic foods but also to a pharmaceutical composition for preventing, treating or ameliorating atrophy, a food composition and a health function Food composition.

FIG. 1 is a graph showing the cytotoxicity observed when cultured in muscle cells after 25, 50, 100, and 200 μg / ml of cymbidium extract.
FIG. 2 is a graph showing the concentration-dependent inhibition and recovery of myocardial necrosis by Cymbidium extract (roots and stem extracts) in muscle cells induced by H ₂ O ₂ in muscle cell necrosis.
Figure 3 is a graph of Cymbidium stem extract showing effects on apoptosis in muscle cells.

The present invention relates to a pharmaceutical composition for preventing or treating muscle atrophy comprising Cymbidium extract as an active ingredient.

In one embodiment of the present invention, the cimbury extract may be extracted with a solvent selected from water, an organic solvent or a mixture thereof.

In one embodiment of the present invention, the organic solvent may be an alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone, ether, chloroform, benzene, hexane, dichloromethane, or a mixture thereof.

In one embodiment of the present invention, the cymbidium extract comprises fractions obtained by further fractionating the primary extract extracted using the extraction solvent with an extraction solvent having a different polarity. For example, the cymbidium extract may be a fraction obtained by extracting with an alcohol having 1 to 5 carbon atoms and then fractionating again with a solvent having a different polarity such as ether, benzene or hexane.

In one embodiment of the present invention, the alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, isopropanol, butanol, isopropanol, ethylene glycol, glycerol, propylene glycol, but is not limited thereto.

In one embodiment of the present invention, at least two kinds of solvents may be used in the fractionation, and each solvent extract may be used sequentially or in combination according to the polarity of the solvent, but not limited thereto.

In one embodiment of the present invention, the produced extract or the fraction obtained by performing the fractionation process may be filtered, concentrated or dried to remove the solvent, and may be subjected to both filtration, concentration and drying . Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a vacuum concentrator, for example, a rotary evaporator. The drying can be performed by, for example, freeze drying.

In one embodiment of the present invention, the cymbidium extract may be an extract of flowers, leaves, stems, roots, fruits, husks, or a mixture thereof of Cymbidium, more preferably stem or root extract.

In one embodiment of the present invention, the cymbidium extract may inhibit myocardial damage, necrosis or apoptosis.

In one aspect of the invention, the atrophy is caused by muscle atrophy caused by loss of muscle tissue caused by not using the muscle, muscle atrophy caused by the muscle itself, or muscle atrophy caused by muscle damage Lt; / RTI >

In one embodiment of the present invention, the cymbidium extract may be included for suppressing muscle aging due to cosmic life or for improving exercise function.

The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier. The composition comprising a pharmaceutically acceptable carrier may be of various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, . In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.

The pharmaceutical composition may be selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, ≪ / RTI >

The composition of the present invention is administered in a pharmaceutically effective amount.

The term "pharmaceutically effective amount " as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will vary depending on the species and severity, age, sex, , Sensitivity to the drug, time of administration, route of administration and rate of excretion, duration of treatment, factors including co-administered drugs and other factors well known in the medical arts. However, for the desired effect, May be administered in an amount of 0.01 to 500 mg / kg, preferably 0.1 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, in an adult, May be administered one to three times.

The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents exhibiting effects of inhibiting myocardial damage, necrosis and apoptosis, and administered sequentially or simultaneously with conventional therapeutic agents. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art.

The term "individual " as used herein refers to all animals, including humans, who have already developed or are capable of developing a disease that can be prevented or treated through the inhibition of myocardial damage, necrosis and apoptosis, Can be effectively prevented and treated by administering the composition to a subject.

The route of administration of the composition may be administered via any conventional route so long as it can reach the target tissue. The composition of the present invention may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, intranasally, intrapulmonarily, or rectally, though it is not intended to be limited thereto. The composition may also be administered by any device capable of transferring the active agent to the target cell.

The present invention relates to a food composition for preventing or improving muscle atrophy containing Cymbidium extract as an active ingredient.

In one embodiment of the present invention, the cimbury extract may be extracted with a solvent selected from water, an organic solvent or a mixture thereof.

In one embodiment of the present invention, the organic solvent may be an alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone, ether, chloroform, benzene, hexane, dichloromethane, or a mixture thereof.

In one embodiment of the present invention, the alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, isopropanol, butanol, isopropanol, ethylene glycol, glycerol, propylene glycol, but is not limited thereto.

In one embodiment of the present invention, the cymbidium extract comprises fractions obtained by further fractionating the primary extract extracted using the extraction solvent with an extraction solvent having a different polarity. For example, the cymbidium extract may be a fraction obtained by extracting with an alcohol having 1 to 5 carbon atoms and then fractionating again with a solvent having a different polarity such as ether, benzene or hexane.

In one embodiment of the present invention, at least two kinds of solvents may be used in the fractionation, and each solvent extract may be used sequentially or in combination according to the polarity of the solvent, but not limited thereto.

In one embodiment of the present invention, the produced extract or the fraction obtained by performing the fractionation process may be filtered, concentrated or dried to remove the solvent, and may be subjected to both filtration, concentration and drying . Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a vacuum concentrator, for example, a rotary evaporator. The drying can be performed by, for example, freeze drying.

In one embodiment of the present invention, the cymbidium extract may be an extract of flowers, leaves, stems, roots, fruits, husks, or a mixture thereof of Cymbidium, more preferably stem or root extract.

In one embodiment of the present invention, the cymbidium extract may inhibit myocardial damage, necrosis or apoptosis.

In one aspect of the invention, the atrophy is caused by muscle atrophy caused by loss of muscle tissue caused by not using the muscle, muscle atrophy caused by the muscle itself, or muscle atrophy caused by muscle damage Lt; / RTI >

 In one embodiment of the present invention, the cymbidium extract may be included for suppressing muscle aging due to cosmic life or for improving exercise function.

Foods according to the present invention may include cube-like extracts, but may include suitable food-aid additives.

The term "food-aid additive " in the present invention means a component which can be added to foods in a supplementary manner, and it can be appropriately selected and used by those skilled in the art as being added to produce health functional foods of each formulation. A coloring agent and a filler, a pectic acid and a salt thereof, an alginic acid and a salt thereof, an organic acid, a protective colloid thickener, a pH adjuster, a stabilizer, a stabilizer and a stabilizer such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, A preservative, a glycerin, an alcohol, a carbonating agent used in a carbonated drink, etc. However, the types of the food-aid additive of the present invention are not limited by the above examples.

In one aspect of the present invention, the present invention relates to a health functional food composition for preventing or improving muscle atrophy comprising Cymbidium extract as an active ingredient.

In one embodiment of the present invention, the cimbury extract may be extracted with a solvent selected from water, an organic solvent or a mixture thereof.

In one embodiment of the present invention, the organic solvent may be an alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone, ether, chloroform, benzene, hexane, dichloromethane, or a mixture thereof.

In one embodiment of the present invention, the alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, isopropanol, butanol, isopropanol, ethylene glycol, glycerol, propylene glycol, but is not limited thereto.

In one embodiment of the present invention, the cymbidium extract comprises fractions obtained by further fractionating the primary extract extracted using the extraction solvent with an extraction solvent having a different polarity. For example, the cymbidium extract may be a fraction obtained by extracting with an alcohol having 1 to 5 carbon atoms and then fractionating again with a solvent having a different polarity such as ether, benzene or hexane.

In one embodiment of the present invention, at least two kinds of solvents may be used in the fractionation, and each solvent extract may be used sequentially or in combination according to the polarity of the solvent, but not limited thereto.

In one embodiment of the present invention, the produced extract or the fraction obtained by performing the fractionation process may be filtered, concentrated or dried to remove the solvent, and may be subjected to both filtration, concentration and drying . Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a vacuum concentrator, for example, a rotary evaporator. The drying can be performed by, for example, freeze drying.

In one embodiment of the present invention, the cymbidium extract may be an extract of flowers, leaves, stems, roots, fruits, husks, or a mixture thereof of Cymbidium, more preferably stem or root extract.

In one embodiment of the present invention, the cymbidium extract may inhibit myocardial damage, necrosis or apoptosis.

In one aspect of the invention, the atrophy is caused by muscle atrophy caused by loss of muscle tissue caused by not using the muscle, muscle atrophy caused by the muscle itself, or muscle atrophy caused by muscle damage Lt; / RTI >

In one embodiment of the present invention, the cymbidium extract may be included for suppressing muscle aging due to cosmic life or for improving exercise function.

The term "health functional food " in the present invention refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings by using raw materials and components having useful functions in the human body. The health functional food of the present invention can be prepared by a method commonly used in the art, and the health functional food of the present invention can be manufactured by the method Unlike general medicines, there is an advantage that there are no side effects that may occur when a drug is taken for a long time by using a food as a raw material, and the portability The health functional food of the present invention is excellent as an adjuvant for enhancing the effect of inhibiting myocardial damage, necrosis and apoptosis It is possible to ingest.

The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, the cymbidium extract according to the present invention is added in an amount of 0.01 to 50% by weight, more preferably 0.1 to 20% by weight in the raw material composition in the production of food. In the case of foods in the form of granules, tablets or capsules, they may be added usually in the range of 0.1 to 100% by weight, preferably 5 to 100% by weight. However, in the case of long-term ingestion intended for health and hygiene purposes or for the purpose of controlling health, the amount can also be used in the above-mentioned range.

There is no particular limitation on the kind of the food. Examples of the food to which the above substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.

The health food of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary foods. The above-mentioned natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tau Martin and stevia extract, synthetic sweetening agents such as saccharine and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 g of the composition of the present invention.

Hereinafter, the present invention will be described in more detail with reference to the following examples, experimental examples, and production examples. It should be understood, however, that the same is by way of illustration and example only and is not intended to limit the scope of the present invention.

[Example]

Example 1: Preparation of Cymbidium extract

Cymbidium was cultivated by the Good Agricultural Practices (GAP) of the Rural Dvelopment Administration (RDA), and in 2009, the Chungbuk provincial voice (GPS: E 128 ° 62'N 36 ° 56 ') It was harvested. Extraction of the sample was performed as follows. 50 g of Cymbidium root and stem dry samples were added with 150 ml of 99% ethanol, and the mixture was reacted at 150 rpm for 48 hours. After filtration, the powder was concentrated under reduced pressure and used as a sample of this experiment.

[Experimental Example]

Experimental Example 1: Cymbidium in muscle cell culture system Cymbidium ) Enhancement of survival rate by antioxidation of extract

(1) Cell culture

Normal muscle cells (C2C12) were cultured in DMEM medium containing 10% fetal bovine serum (FBS). Normal skeletal muscle cells were fixed in 75 ㎠ plastic flask (Falcon Co., England) with 10% FBS, 7.5% NaHCO ₃ 150 μg / ml, glutamine 58.4 μg / ml and antibiotics / antimycotics 4.4 μl / ml in DMEM medium at 37 ° C and 5% CO ₂ . The cell line was maintained by secondary culture once every 2-3 days.

(2) Cell quantification

Cells were removed from the bottom of the flask by treatment with 0.25% trypsin / EDTA followed by washing with CMF-PBS (calcium magnesium free-phosphate buffered saline, pH 7.2) Neutralized with the culture medium and centrifuged (1200 rpm, 5 min). The culture medium was added to the pellet of the remaining cells and repeatedly inhaled with a sterile pipette to make a single cell suspension. Trypan blue was mixed with the cell suspension at a ratio of 9: 1, were measured using a hemocytometer.

(3) Cytotoxicity measurement

To determine the toxicity of Cymbidium extract, MTT assay was used. That is, normal muscle cells (C2C12) were dispensed into a 24-well plate at a density of 1 × 10 ⁵ cells / well. The cells were cultured in an incubator at 37 ° C and 5% CO ₂ for 24 hours and cultured for 24 hours at a concentration of 0, 25, 50, 100 and 200 μg / ml. An MTT solution obtained by dissolving 0.01 g of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) in 10 ml of CMF-PBS (calcium magnesium free-phosphate buffered saline, pH 7.2) And reacted in an incubator for 1 hour, and then the medium was removed. Then, DMSO (dimethyl sulfoxide) was dispensed into each well and transferred to 96 wells. The absorbance was measured to determine the cytotoxicity of the cymbidium extract.

As a result, the survival rate was 100% when the Cymbidium extract was not added and the survival rate was similar to that when the Cymbidium extract was not added in the addition group with Cymbidium extract (FIG. 1).

Therefore, it was confirmed that the cymbidium extract used in this experiment did not show toxicity to cultured muscle cells.

(4) H ₂ O ₂ Of Cystic Muscle Cell Necrosis Induced by Cymbidium ) Effect of extract concentration

In order to observe the effect of concentration of Cymbidium extract, muscle cells were first placed in a 24-well plate at 1 × 10 ⁵ cells / well and cultured in a CO ₂ incubator. Then, cymbidium extracts were added at concentrations of 0, 25, 50, 100, and 200 μg / ml, respectively, and cultured for 24 hours at 5% CO ₂ . After incubation, H ₂ O ₂ was added at a concentration of 1 mM and incubated for 1 hour. Then, 50 μl of MTT solution was dispensed into each well. After reacting in an incubator for 1 hour, the medium was removed. Then, DMSO (Dimethyl Sulfoxide) was dispensed and transferred to 96 wells respectively, and the absorbance was measured to determine its effect.

As a result, the cell survival rate was recovered as the concentration of Cymbidium increased from 0 μg / ml to 200 μg / ml (FIG. 2). Therefore, it was proved that the concentration of cymbidium extract was increased in a concentration-dependent manner.

(5) H ₂ O ₂ Cymbidium for Muscle Cell Apoptosis by Cymbidium ) Effect of extract

In order to observe the Cymbidium (Cymbidium) effect of the extracts on apoptosis (apoptosis) muscle cells by H ₂ O _2, first insert the cover glass in 6 well muscle cells 2 × 10 ⁵ cells / well placed such that the CO ₂ incubator Lt; / RTI > Then, cymbidium extracts were added at concentrations of 0, 25, 50, 100, and 200 μg / ml, respectively, and cultured for 24 hours at 5% CO ₂ . After incubation, H ₂ O ₂ was added at a concentration of 1 mM and incubated for 1 hour. DAPI (4 ', 6-diamidino-2-phenylindole) was stained and its effect was determined.

As a result, apoptosis of muscle cells was induced by H ₂ O ₂ , and it was confirmed that Cymbidium- added group prevented apoptosis (FIG. 3).

[Manufacturing Example]

Production Example 1. Preparation of powder

Cymbidium extract .................. 10 mg

Sucrose ......................... 100 mg

Talc ............................. 10 mg

The above components are powdered and mixed, and filled in an airtight container to prepare a powder.

Production Example 2 Manufacture of tablets

Cymbidium extract ................... 20 mg

Lactose .............................. 100 mg

Starch .............................. 100 mg

Magnesium stearate ............... Quantity

The above components are mixed and tablets are prepared by tableting according to a conventional method for producing tablets.

Production Example 3. Preparation of capsules

Cymbidium extract .................... 10 mg

Lactose ............................... 50 mg

Starch ............................... 50 mg

Talc ............................... 2 mg

Magnesium stearate .................. Amount

The above components are mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

Production Example 4. Preparation of Granules

Cymbidium extract .................... 10 mg

Soybean extract ........................ 50 mg

Glucose ............................. 200 mg

Starch ............................... 500 mg

After mixing the above components, 100 mL of 30% ethanol is added, and the mixture is dried at 60 ° C to form granules, which are filled in a capsule to prepare granules.

Production Example 5. Preparation of a pellet

Cymbidium extract .................... 20 mg

Lactose ............................... 1,500 mg

Glycerin ........................... 1,500 mg

Starch ............................... 980 mg

After mixing the above components, they are prepared so as to be 4 g per one ring according to a conventional method for producing a pellet.

Production Example 6. Production of liquid agent

Cymbidium extract ..................... 100 mg

Sugar ................................ 20 g

Isomerization sugar ............................ 20 g

Lemon flavor .............................. Suitable amount

Purified water is added to the whole ................ 100 ml

The above components are mixed according to a conventional method for preparing a liquid preparation, filled in a 100 ml brown bottle, and sterilized to prepare a liquid preparation.

Preparation Example 7. Preparation of injection

Cymbidium extract ..................... 1.0 mg

Sodium Metabisulfite ............... 0.5 mg

Methylparaben .......................... 0.8 mg

Propylparaben ........................ 0.1 mg

Sterilized distilled water for injection

The above ingredients are mixed and made into 3 ml by a conventional method, and then filled into a 3 ml capacity ampoule and sterilized to prepare an injection.

Production Example 8. Preparation of Health Functional Foods

Cymbidium extract 20 mg, Vitamin A acetate 70,, Vitamin E 1.0 mg, Vitamin B1 0.13 mg, Vitamin B 0.15 mg, Vitamin B6 0.5 mg, Vitamin B12 0.2 mg, Vitamin C 10 mg, Biotin 10 mg, Amide 1.7 mg, folic acid 50,, calcium pantothenate 0.5 mg, inorganic mixture suitable amount, ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, potassium phosphate monobasic 15 mg, dibasic calcium phosphate 55 mg, potassium citrate 90 mg of calcium carbonate, 100 mg of calcium carbonate, and 24.8 mg of magnesium chloride.

Production Example 9. Preparation of health drinks

Cymbidium extract (20 mg), citric acid (1000 mg), oligosaccharide (100 g), plum concentrate (2 g), taurine (1 g) and purified water.

Preparation Example 10. Preparation of confectionery

10 mL of the cymbidium extract of the present invention is added to 5 g of butter and 10 mL of milk to 100 g of wheat flour, and the mixture is used to prepare cookies, crackers and snacks.

Claims (17)

A pharmaceutical composition for preventing or treating muscle atrophy comprising, as an active ingredient, an extract obtained by extracting Cymbidium with a solvent selected from water, an organic solvent or a mixture thereof.
delete The method according to claim 1,
Wherein the organic solvent is selected from the group consisting of alcohols having 1 to 5 carbon atoms, ethyl acetate, acetone, ether, chloroform, benzene, hexane, dichloromethane and mixed solvents thereof.
The method according to claim 1,
Wherein the cymbidium extract is an extract of flowers, leaves, stems, roots, fruits, husks, or a mixture thereof of Cymbidium.
The method according to claim 1,
Wherein the cymbidium extract is an extract of stem or root of cymbidium.
The method according to claim 1,
Wherein the cymbidium extract inhibits myocardial damage, necrosis, or apoptosis.
The method according to claim 1,
Wherein the atrophy is atrophy caused by muscle atrophy caused by loss of muscle tissue caused by not using muscle, muscle atrophy caused by muscle sickness, or muscle nerve damage. ≪ / RTI >
The method according to claim 1,
Wherein the cymbidium extract is contained for the purpose of suppressing muscle aging due to cosmic life or for improving exercise function.
A food composition for improving muscle atrophy comprising, as an active ingredient, an extract obtained by extracting Cymbidium with a solvent selected from water, an organic solvent or a mixture thereof.
delete 10. The method of claim 9,
Wherein the organic solvent is an alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone, ether, chloroform, benzene, hexane, dichloromethane, or a mixed solvent thereof.
10. The method of claim 9,
Wherein the cymbidium extract is an extract of flowers, leaves, stems, roots, fruits, husks, or a mixture thereof of Cymbidium.
10. The method of claim 9,
Wherein the cymbidium extract is an extract of stem or root of cymbidium.
10. The method of claim 9,
Wherein the cymbidium extract inhibits myocardial damage, necrosis, or apoptosis.
10. The method of claim 9,
Wherein the atrophy is atrophy caused by muscle atrophy caused by loss of muscle tissue caused by not using muscle, muscle atrophy caused by muscle sickness, or muscle nerve damage. Food composition for improvement.
10. The method of claim 9,
Wherein the cymbidium extract is contained for the purpose of suppressing muscle aging due to cosmic life or for improving exercise function.
A health functional food composition for improving muscle atrophy comprising an extract obtained by extracting Cymbidium with a solvent selected from water, an organic solvent or a mixture thereof.

Images